New Drug Pricing Policies Will Come at Great Expense
Regarding prescription drug costs, politicians have officially approached the “be careful what you wish for” territory. Knee-jerk ...
New Drug Pricing Policies Will Come at Great Expense
The Inflation Reduction Act Will Lead to Fewer New Medicines
Commentary: What impact the Inflation Reduction Act can have on Boston biotechs
The High Cost of Price Controls on Eliquis and Other Drugs
CMS Finalizes Policy to Facilitate Faster Biosimilar Uptake but Follow-on Policies and Actions Still Needed
Statement by We Work For Health Executive Director Dan Leonard on World IP Day
Commonsense Policies Needed to Lower Healthcare Costs and Improve Patient Access While Protecting Drug Development Pipeline
Paths to Progress: Understanding Policy’s Broad Impact on US Leadership in Biopharma